Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metabolic Syndrome AND Diabetes Mellitus Type 2 AND Diabetes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Metabolic Syndrome AND Diabetes Mellitus Type 2 AND Diabetes. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-003207-35 Sponsor Protocol Number: APCP-115,amendment Start Date*: 2013-08-13
    Sponsor Name:Karolinska University Hospital Solna
    Full Title: Effects of ARA 290, a non-hematopoietic erythropoietin analog, on glucose tolerance, insulin secretion, insulin sensitivity and long-term glucose control in individuals with prediabetes and/or dru...
    Medical condition: For the complementary visits; up to 12 Subjects with Prediabetes (impaired fasting glucose, impaired glucose tolerance) or diet-treated type 2 diabetes, will be chosen from the currently approved c...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10065542 Prediabetes LLT
    17.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001454-33 Sponsor Protocol Number: DEXBASU Start Date*: 2017-08-07
    Sponsor Name:Dr. Albert Lecube Torello
    Full Title: A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surg...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000942-39 Sponsor Protocol Number: NL34476.068.11 Start Date*: 2011-06-20
    Sponsor Name:CTMM, the Center for Translational Molecular Medicine
    Full Title: Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.
    Medical condition: This trial includes overweight patients with both hypothyroidism and type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006118-15 Sponsor Protocol Number: CLAF237ADE07 Start Date*: 2012-06-13
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-...
    Medical condition: type-2 diabetes mellitus with pre-existing cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021069-63 Sponsor Protocol Number: BCB109(H8O-MC-GWDQ) Start Date*: 2011-06-23
    Sponsor Name:Amylin Pharmaceuticals, LLC
    Full Title: A randomized, placebo, controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exenatide Once Weekly in patients with type 2 diabetes mellitus
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) LV (Completed) AT (Completed) GB (Completed) CZ (Completed) SK (Completed) HU (Completed) BG (Completed) IT (Completed) BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003049-16 Sponsor Protocol Number: CL007_140 Start Date*: 2011-08-29
    Sponsor Name:ChemoCentryx, Inc
    Full Title: A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus, nephropathy, albuminuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.0 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    14.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    14.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    14.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004250-18 Sponsor Protocol Number: PIAII Start Date*: 2016-02-19
    Sponsor Name:Karolinska Institutet
    Full Title: Acupuncture or Metformin for Insulin Resistance in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial
    Medical condition: Polycystic ovary syndrome (PCOS) affects 10 to 15% of all women and is the most common female endocrine and metabolic disorder during the reproductive years. PCOS is characterized by anovulation, h...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    18.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021922-36 Sponsor Protocol Number: 2010-352-UREMINC Start Date*: 2011-05-23
    Sponsor Name:Department of Nephrology, Rigshospitalet, University of Copenhagen
    Full Title: Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.
    Medical condition: 1) Patients with type 2 diabetes (T2D) and no or severely reduced kidney function, depending on chronic dialysis treatment. 2) Patients with T2D and normal kidney function.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10041244 - Social circumstances 10012347 Dependence on renal dialysis LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012140-16 Sponsor Protocol Number: 28431754DIA3008 Start Date*: 2010-01-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ 28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
    Medical condition: Type 2 diabetes mellitus and history or high risk cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    19.0 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) HU (Completed) EE (Completed) CZ (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002348-99 Sponsor Protocol Number: AUTH88622 Start Date*: 2014-09-22
    Sponsor Name:Aristotle University Thessaloniki
    Full Title: A randomised, double blind, placebo-controlled study of the effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus
    Medical condition: Hypertention, Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-000671-16 Sponsor Protocol Number: BC28027 Start Date*: 2013-02-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities
    Medical condition: - Stable Cardiovascular Disease and - Diabetes Mellitus Type 2 or Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    14.1 10027433 - Metabolism and nutrition disorders 10036481 Pre-diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) AT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002336-15 Sponsor Protocol Number: 578 Start Date*: 2011-08-31
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: The effect of prednisolone versus hydrocortisone as glucocorticoid replacement therapy on hypoglycaemia frequency in people with Type 1 diabetes and adrenal insufficiency: a pilot study.
    Medical condition: Type 1 diabetes and adrenal insufficiency.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10001367 Adrenal insufficiency PT
    13.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002268-15 Sponsor Protocol Number: EMPA-1 Start Date*: 2016-09-29
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF EMPAGLIFLOZIN, A SGLT-2 INHIBITOR, ON ENDOGENOUS GLUCOSE PRODUCTION AND PLASMA GLUCAGON LE...
    Medical condition: Patients with end-stage renal disease (ESRD) with or without Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    21.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010967-18 Sponsor Protocol Number: DM-UMCU-01 Start Date*: 2009-11-11
    Sponsor Name:University Medical Centre Utrecht
    Full Title: Effect of adding vildagliptin to start of insulin treatment in combination with metformin in patients with type 2 diabetes
    Medical condition: patients with type 2 diabetes, failing on maximal oral glucose-lowering drugs, starting on insulin therapy in combination with standard metfromin (2 x 850)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012852-26 Sponsor Protocol Number: EFC11319 Start Date*: 2010-09-06
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Estudio multicéntrico doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, para evaluar los eventos cardiovasculares durante el tratamiento con lixisenatide en pacientes con dia...
    Medical condition: Diabetes tipo II ___________________ Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GB (Completed) LT (Completed) EE (Completed) DK (Completed) LV (Completed) IT (Completed) NL (Completed) SE (Completed) FR (Completed) FI (Completed) BG (Completed) BE (Completed) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002507-34 Sponsor Protocol Number: GSN000200 Start Date*: 2014-02-20
    Sponsor Name:Genkyotex Innovation SAS
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    17.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000828-19 Sponsor Protocol Number: NN9535-4662 Start Date*: 2021-01-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed) ES (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002878-50 Sponsor Protocol Number: NN9535-4321 Start Date*: 2019-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
    Medical condition: Diabetes Mellitus, Type 2 Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Completed) SK (Completed) BG (Completed) DE (Completed) ES (Ongoing) FR (Completed) PL (Completed) BE (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000829-44 Sponsor Protocol Number: H9X-MC-GBDX Start Date*: 2012-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chroni...
    Medical condition: Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:53:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA